The FDA grants Genentech’s sBLA for Avastin (bevacizumab) plus chemotherapy Priority Review for the treatment of women with recurrent platinum-resistant ovarian cancer.
Your search for bevacizumab returned 50 results
Genentech announced that the Food and Drug Administration (FDA) has approved Avastin (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer.
Genentech announced positive results from its Phase 3 study of Avastin (bevacizumab) plus radiation and temozolomide (Temodar; Merck & Co., Inc.) chemotherapy in patients with newly diagnosed glioblastoma.
The conversion from provisional to full approval was based on totality of evidence of Avastin in glioblastoma.
The use of Prophage Series G-100 (HSPPC-96; Agenus) in combination with current standard of care (radiation and temozolomide) demonstrates improvement in progression free survival in patients with newly diagnosed glioblastoma multiforme (GBM).
The FDA has confirmed that a counterfeit version of Roche’s Altuzan 400mg/16mL (bevacizumab), an injectable cancer medication, found in the US contains no active ingredient.
Genentech announced that the FDA has expanded the use of Avastin (bevacizumab) in combination with fluoropyrimidine-based irinotecan or oxaliplatin chemotherapy as second-line treatment for patients with metastatic colorectal cancer (mCRC) whose cancer has progressed on a first-line Avastin-containing regimen.
REACH-2 was a randomized, double-blind, placebo-controlled trial that enrolled 292 patients with hepatocellular carcinoma (HCC) who were intolerant to, or had disease progression while on or following treatment with sorafenib and had a high alpha-fetoprotein (AFP-High) defined as AFP ≥400ng/mL.
Study patients who received Avastin plus chemotherapy followed by Avastin alone, had a greater median PFS vs patients who received chemotherapy alone (18.2 months vs 12 months; hazard ratio [HR] 0.62, 95% CI, 0.52-0.75; P<.0001).
Genentech, a member of the Roche Group, announced results from the Phase 3 AVAglio study; the study evaluated Avastin (bevacizumab) in combination with radiation and temozolomide (Temodar; Merck) chemotherapy in patients with newly diagnosed glioblastoma.